EUVIMEDDescoperă EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance

Saied Froghi, Astero Klampatsa, Brian Davidson

Frontiers in Immunology · 2026-05-08 · 17

DOI: 10.3389/fimmu.2026.1757504 ↗

At a glance

Übersichtsarbeit in Frontiers in Immunology, published online on 2026-05-08. Written by Saied Froghi and 2 co-authors. Institution: Division of Surgery & Interventional Sciences, Royal Free Hospital, University College London, London, United Kingdom. Major MEDLINE topics: Cholangiocarcinoma, Bile Duct Neoplasms, Immunotherapy, Adoptive. Cited 1 times so far (Crossref); 327 references. The full text is freely available (open access, CC BY 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

The rising global incidence and dismal prognosis of cholangiocarcinoma (CCA) underscore the profound limitations of standard therapies. While chimeric antigen receptor (CAR)-based cellular immunotherapies represent a paradigm shift in oncology, their success in CCA is fundamentally constrained by a desmoplastic, immunosuppressive tumour microenvironment (TME) and significant tumour antigen heterogeneity. This review advances the thesis that overcoming these barriers requires an integrated approach combining multi-antigen, armoured CAR designs with rational adjuvant strategies (i.e combination therapy). We provide a comparative analysis of key tumour-associated antigens (TAAs)-including MUC1, c-MET, and the cancer stem cell marker CD133-evaluating their expression profiles, preclinical efficacy, and clinical status. The review further deconstructs the core mechanisms of therapeutic resistance in CCA-spanning physical, immunological, and metabolic barriers-and map them to next-generation engineering strategies designed to counteract them. In a novel synthesis, we explore the synergistic potential of combining CAR therapies with checkpoint inhibitors and immunomodulatory natural compounds. Critically appraising the current clinical trial landscape, we identify key weaknesses and propose strategic recommendations for biomarker-driven, adaptive trial designs. Finally, we present a forward-looking, four-pillar roadmap for future research, positioning the integration of advanced CAR engineering, multi-antigen platforms, synergistic adjuvants, and alternative effectors as the definitive research agenda for translating the promise of cellular immunotherapy into a clinical reality for CCA.

Subjects

MeSH terms (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsImmunotherapy, AdoptiveHumansTumor MicroenvironmentAnimalsAntigens, NeoplasmDrug Resistance, NeoplasmImmunotherapyReceptors, Chimeric AntigenCombined Modality Therapy

Author keywords

ACTCCATMEadoptive cell therapyarmoured carscholangiocarcinomacombination immunotherapyimmune checkpoints

Substances

Antigens, NeoplasmReceptors, Chimeric Antigen

Authors and institutions

  • Division of Surgery & Interventional Sciences, Royal Free Hospital, University College London, London, United Kingdom.
  • Thoracic Oncology Immunotherapy Group, Division of Cancer Biology, Institute of Cancer Research, Sutton, United Kingdom.

Cite

APA

Froghi, S., Klampatsa, A., & Davidson, B. (2026). Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1757504

Vancouver

Froghi S, Klampatsa A, Davidson B. Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1757504

BibTeX
@article{Froghi2026,
  author = {Froghi, Saied and Klampatsa, Astero and Davidson, Brian},
  title = {Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1757504}
}
Start for free →